Fórum dedicado à discussão sobre os Mercados Financeiros - Bolsas de Valores
http://caldeiraodebolsa.jornaldenegocios.pt/
http://caldeiraodebolsa.jornaldenegocios.pt/viewtopic.php?f=3&t=54880
Enviado: 15/3/2007 10:01GAB Escreveu:[quote="luka
2/com o estocastico a dar sinal
Enviado: 15/3/2007 9:58
[/quote]
Enviado: 14/3/2007 23:37GAB Escreveu:Se houvesse AUMENTO DE VOLUME seria mais interessante...
Enviado: 12/3/2007 22:27Enviado: 12/3/2007 22:13
inicio de swing UP
Enviado: 10/3/2007 16:29Insmed Incorporated, a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders in the United States.
Insmed Announces Restructure, Settlement Ending IPLEX(TM) Patent Dispute
Restructure Improves Financial Position and Allows Company to Focus on Clinical Development for HIV-Related Condition and Myotonic Muscular Dystrophy
RICHMOND, Va., Mar 07, 2007 (BUSINESS WIRE) -- Insmed Inc., (NASDAQ: INSM) announced today that it has restructured its operations as a result of the litigation settlement with Tercica Inc. (NASDAQ: TRCA) and Genentech Inc. (NYSE: DNA), which was announced yesterday, ending all litigation between the parties.
Geoffrey Allan Ph. D., President, CEO and Chairman of Insmed, commented: "With the lawsuit behind us we can now focus all our efforts on developing IPLEX for the promising indications we have already identified, and with the License and Development agreement with Tercica and Genentech in place we believe we are well positioned for success." Dr. Allan added that, "The end of litigation removes a cloud from the Company's future and the consequent restructuring allows for an improved financial position."